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The rapidly growing popularity of methamphetamine use in Iran has posed a new health challenge to the Iranian
health sector. Methamphetamine-associated psychosis (MAP) has been frequently reported in Iran in recent years.
Although methamphetamine use and MAP are considerable health problems in Iran but there is still a need to
conduct epidemiological studies on the prevalence of MAP and its health-related problems. The present paper
emphasizes that health policy makers should consider the immediate needs of drug users, their families and the
community to be informed about the detrimental health effects associated with MAP. Although MAP could be
managed by prescribing benzodiazepines and psychiatric medications but the most effective regime for stabilizing
patients with MAP still needs to be studied in Iran. Constant collaborations among psychiatric services and
outpatient psychotherapeutic services should be established to successfully manage MAP in Iran. Iranian clinicians
especially emergency medicine specialists should be informed about the differences between the two forms of
transient and recurrent MAP in order to implement appropriate pharmacological therapies to manage MAP. It is
hoped that special training courses are designed and implemented by health policy makers to inform clinicians,
health providers and especially emergency medicine specialists to effectively deal with MAP.Editorial
For centuries, opium and opium residues have been used
by Iranians but in recent years, methamphetamine (MA)
use has emerged as an epidemic health concern among
Iranian substance users [1]. Methamphetamine is known
as a synthetic derivative of amphetamine, but due to the
addition of a methyl group in its chemical structure, it
has lipid solubility, allowing more rapid transport of the
drug across the blood–brain barrier [2].
Methamphetamine use and abuse can result in
methamphetamine-associated psychosis (MAP) which has
a recurrent nature [3]. MAP is characterized by auditory
or visual hallucinations, ideas of reference, persecutory
delusions, thought reading, strange or unusual beliefs,
delusions of reference and thought insertion [4]. The
incidence and severity of MAP are related to high doses
of methamphetamine use, the routes of administration,
and duration of regular use [5,6]. MAP is more likely to
occur in methamphetamine patients even after adjusting
with psychotic disorders [7,8]. The presence of MAP is* Correspondence: a.mehrjerdi@gmail.com
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However, susceptibility to psychotic episodes could prolong
for years after prevention from methamphetamine use [3].
Studies show that methamphetamine use [3], using other
drugs [9] and psychosocial stressors [10] could trigger the
relapse of MAP. MAP is also associated with considerable
health service utilization and increased psychiatric
symptoms over time [11]. Chronic MAP is persistent and
so similar to those of schizophrenia. Studies show that
susceptibility to MAP could last for years after preventing
from methamphetamine use [5].
Currently, methamphetamine use has rapidly emerged
and developed in Iran [12,13]. A recent rapid situational
assessment (RSA) of substance use showed that only a
small group of Iranian substance users (3.6%) reported
methamphetamine as their main drug of abuse [14] but
in the past several years, the price of methamphetamine
has dramatically decreased. Current nonofficial estimates
suggest that methamphetamine is the second or third
illicit drug in Iran [14] and an increasing number of
patients with MAP are admitted to Iranian psychiatric
hospitals [15].
In a study on the symptoms and treatment of MAP
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department setting of Iranian educational and therapeutic
center of psychiatry because of suicide attempts, auditory
hallucinations and persecutory delusions. The patient was
treated with prescribing antipsychotic medications and
experienced a short recurrence of MAP during abstaining
from methamphetamine use, as well as a MAP episode
although he was receiving antipsychotic medications [16].
Omidvar and Sharifi (2012) examined a patient who
was diagnosed with MAP and eye autoenucleation. The
patient had delusions of being in control and believed
that others were using his eyes. He was diagnosed with a
first episode of MAP and did not report MAP symptoms
in the absence of methamphetamine use but he was
treated with six sessions of electroconvulsive therapy
(ECT) and prescribing psychiatric medications [17]. A
study on 50 methamphetamine abusers recruited from
the Iranian legal medical organization in Tehran showed
that delusion, mood instability, disorientation, and
self-mutilation were prevalent among the patients [18].
In another study, the clinical files of 111 metham-
phetamine patients who had been admitted to a central
hospital in Tehran from April 2008 to April 2010 were
reviewed. The study results showed that the most prevalent
psychotic symptoms were persecutory delusions (82%),
auditory hallucinations (70.3%), reference delusions (57.7%),
visual hallucinations (44.1%), grandiosity delusions (39.6%)
and jealousy delusions (26.1%). The mean duration of
admission and psychotic episodes were 21.43 and 17.37
days respectively. In seven cases (8.75%), MAP continued
for more than one month [19]. Methamphetamine-related
health problems such as MAP have changed the profile of
patients who utilize psychiatric services in Iran [20].
Because of heavy use, many of such cases are characterized
by delusions, hallucinations, anxiety, insomnia, mood
disturbances, suicide, violent behaviors and homicidal
ideations [20]. This is consistent with some studies in
other countries which indicate that heavy use of metham-
phetamine contributes to a variety of severe psychiatric
problems including MAP [21].
It should be noted that the rapidly growing popularity of
methamphetamine use has posed a new health challenge
to the Iranian health sector. MAP is associated with a
range of acute and chronic health and social problems that
need to be considered during the course of treatment
especially in emergency department settings, and psychi-
atric and general hospitals. In order to effectively deal with
MAP in Iran, several issues should be considered by
health policy makers. Although MAP is prevalent among
methamphetamine users in Iran, epidemiological studies
on the prevalence of MAP and its health-related problems
should be conducted.
The negative effects of MAP on methamphetamine
patients, and the community should be considered byhealth policy makers. Nationwide drug education should
be designed and implemented to inform drug users, their
families and the community about the harms associated
with MAP and the necessity of immediate referrals of such
cases to emergency department settings of psychiatric
hospitals. MAP could be treated with prescribing psychi-
atric medications and benzodiazepines in a supportive
non-judgmental relationship. Atypical antipsychotics
have become first line treatments for psychotic disorders,
especially first episode psychosis [22]. Recently, case
reports of successful MAP treatment with atypical
antipsychotics such as Olanzapine [23], Risperidone
[24] and Quetiapine [25] have been reported. Such
studies have been conducted in other countries such as
USA and Australia. There is an immediate need for Iran
to devise a treatment protocol to pharmacologically manage
MAP according to its health and medical-related
conditions.
Little is known about the pharmacological therapies of
patients with MAP in Iran. Moreover, the most effective
regime for stabilizing patients with MAP still needs to
be studied in Iran. Once, the pharmacological therapy of
MAP is implemented in a psychiatric hospital, referring
patients to outpatient drug use treatment clinics is
implemented. In many instances, the involvements of such
services include outpatient psychotherapeutic services and
there is still a need to establish constant collaborations
among psychiatric services and outpatient psychothera-
peutic services to successfully manage MAP.
Methamphetamine users are vulnerable to MAP, either
from exacerbation of symptoms of underlying psychotic
disorders [26] or emerging new psychotic symptoms during
intoxication and withdrawal stages [27] and recurrence
can occur in response to psychological stressors even in
the absence of methamphetamine use [28].
Iranian clinicians should know that psychotic symptoms
tend to persist in some patients. Therefore, the distinction
between persistent MAP and a primary transient MAP
has grown increasingly important. Iranian clinicians
especially emergency medicine specialists should be
informed about the differences between these two forms
of MAP and recurrence of MAP in order to implement
appropriate pharmacological therapies to manage MAP.
Primary and emergency health care providers, mental
health and substance abuse treatment service providers
need to be trained to distinguish between MAP, other
forms of toxic psychosis, and primary psychosis. A further
challenge to primary and emergency health care service
providers lies in the detection and management of transient
MAP and persistent MAP. This issue needs attention by
health policy makers.
To sum up, as MAP negatively influences Iran, new
nationwide and research-oriented strategies should be
designed and implemented to meet the increasing needs
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emergency medicine specialists to effectively deal with
MAP. Given the challenges that MAP has posed to
health professionals and the community, the role of the
health sector in the provision of evidence-based treatment
for MAP is emphasized. In order to fulfill this role, it is
important that the health sector such as the medical
schools also provides health care professionals with
evidence-based information and training related to the
diagnosis and management of MAP.
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